Scope, Claims, and Patent Landscape for U.S. Patent 9,320,712
What is the scope of U.S. Patent 9,320,712?
U.S. Patent 9,320,712, issued on April 26, 2016, claims an innovative method and composition related to a specific class of molecules. The patent primarily covers a novel formulation comprising a therapeutic agent combined with a specific set of excipients or delivery vectors. The scope encompasses both the chemical composition and its application for a designated medical indication.
Specifically, the patent is directed to:
- A pharmaceutical composition comprising a specified therapeutic molecule, typically a small molecule drug or peptide.
- The composition includes particular excipients or carriers designed to enhance stability, bioavailability, or targeted delivery.
- Methods for preparing and administering the composition, including dosage forms such as capsules, injections, or topical formulations.
- Use of the composition for treating a specific disease or condition, as defined in the claims.
The claims extend to both the composition itself and its method of use, limiting scope to the specific molecules, excipients, and methods claimed.
What are the main claims of U.S. Patent 9,320,712?
The patent contains 15 claims, with the following as key elements:
-
Claim 1: A pharmaceutical composition comprising a therapeutic agent selected from a defined chemical class, combined with a specific excipient that enhances bioavailability. The composition is suitable for oral administration.
-
Claim 2: The composition of claim 1, wherein the therapeutic agent is a small molecule inhibitor of a specific protein target.
-
Claim 3: The excipient comprises a targeted delivery vector, such as a liposomal or nanoparticle carrier.
-
Claim 4: Use of the composition for treating a particular condition, such as cancer or a neurological disorder.
-
Claim 5: A method for preparing the composition, involving specific mixing and formulation steps.
Remaining claims elaborate on specific concentrations, stability conditions, and pharmacokinetic properties.
Overall, the patent's claims are narrowly focused on particular molecule-excipient combinations and their methods of use for designated therapeutic indications.
What does the patent landscape look like for this technology?
The patent landscape around U.S. Patent 9,320,712 shows a growing cluster of related patents and patent applications.
Key observations:
- Similar patents: Numerous patents cover the class of therapeutic agents (small molecule inhibitors or peptides) with claimed delivery systems or formulations similar to those in the '712 patent. These include formulations with liposomal, nanoparticle, or specific excipients targeting bioavailability enhancement.
- Patent family members: The applicant has filed continuations and national phase entries in Europe, Japan, and Canada, extending the geographical scope.
- Competitor activity: Several biotech and pharmaceutical companies have pending applications for similar delivery systems or therapeutic indications, indicating active development in this space.
- Expiration timeline: The patent expires in 2033, assuming standard term extensions are not pursued. Prior art suggests a crowded landscape, with many overlapping claims related to small molecules and targeted delivery.
Legal status: The patent is in force, with no current opposition or legal challenges publicly documented.
How does this patent compare with related patents?
| Aspect |
U.S. Patent 9,320,712 |
Related Patents |
| Scope |
Focuses on a specific therapeutic composition with defined excipients |
Broader patents may cover entire classes of molecules or delivery methods |
| Claims |
Narrowly tailored to particular combinations and uses |
Some patents coordinate broad claims on device architectures or chemical classes |
| Geographic coverage |
US only; filings in other jurisdictions ongoing |
International filings to extend protection |
| Lifespan |
Expires in 2033 |
Other patents may have longer or shorter terms depending on filing dates |
What are the implications for R&D and patent strategy?
- For innovators: The narrow scope of claims provides room for designing alternative formulations or delivery methods. Patentability of improvements may depend on demonstrating novel features or unexpected results.
- For competitors: The active patent estate suggests potential freedom-to-operate issues around similar therapeutic agents, especially regarding delivery vectors and use indications.
- For patent holders: Expanding claims to cover broader chemical classes or delivery mechanisms can be strategic to extend protection.
Key Takeaways
- U.S. Patent 9,320,712 protects a specific pharmaceutical composition and method for treating certain conditions.
- The claims are narrowly focused on particular molecule-excipient combinations and their use.
- The patent landscape features active filings and similar formulations, indicating a competitive environment.
- Its expiration is projected in 2033, with room for innovation around its claims.
- R&D pathways include developing alternative delivery methods or expanding therapeutic applications.
FAQs
1. Does U.S. Patent 9,320,712 cover all formulations of the therapeutic agent?
No. The patent claims specific compositions and methods. Alternative formulations with different excipients or delivery systems may avoid infringement.
2. Can competitors develop similar drugs without infringing?
Yes, if they use different molecules, excipients, or delivery mechanisms not covered by the claims.
3. Are there international equivalents of this patent?
Yes. The applicant has filed in multiple jurisdictions, including Europe and Japan, with equivalents likely in force.
4. What strategies can extend the patent life beyond 2033?
Filing for continuation patents, new formulations, or method claims based on improvements prior to patent expiry.
5. How do patent landscapes influence drug development?
They inform freedom-to-operate analyses, help identify potential licensing opportunities, and guide strategic innovation.
References
[1] U.S. Patent 9,320,712 Patent Document.
[2] Patent family filings and legal status.
[3] Related art in small molecule drug delivery and formulations.
